DPP-4 inhibitors are widely used in clinical practice as oral antidiabetic agents and may also improve gut barrier function via GLP-2-dependent mechanisms in murine obesity models [107]. This evidence concerns the gene DPP4 and obesity due to melanocortin 4 receptor deficiency.